Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2011-04-01 Transaction in Own Shar…
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares 2011
Transaction in Own Shares Classification · 100% confidence The document text, written in Danish, explicitly discusses Novozymes initiating a share buyback program ('aktietilbagekøbsprogram') under a specific EU regulation (No. 2273/2003, 'Safe Harbour'). It specifies the total amount (400 million DKK) and the period (Feb 11, 2011, to Dec 31, 2011). This action directly relates to the company transacting in its own shares. The classification code corresponding to 'Report of the company buying back or selling its own shares (share repurchase/issuance)' is POS (Transaction in Own Shares). The document is short and appears to be an announcement of this activity.
2011-04-01 Danish
Transaction in Own Shares 2011
Transaction in Own Shares Classification · 99% confidence The document details specific transactions related to a share buyback program ('aktietilbagekøbsprogram') conducted by Novozymes between February and December 2011, including the number of shares bought and the transaction value. It concludes by stating the total number of own shares held. This content directly relates to the company managing its own stock, which falls under the category of 'Transaction in Own Shares' (share repurchase/issuance). The code for this is POS.
2011-04-01 English
Regulatory Filings 2011
Regulatory Filings Classification · 99% confidence The document explicitly states that Novozymes initiated a 'share buyback program' for an amount up to DKK 400 million. This action directly corresponds to the definition of a company buying back its own shares. The relevant filing type is 'Transaction in Own Shares' (POS). The document length is very short (407 chars), but it is a direct announcement of the transaction program itself, not merely an announcement that a report is attached, making POS more specific than RPA or RNS.
2011-03-25 English
Transaction in Own Shares 2011
Transaction in Own Shares Classification · 99% confidence The document text details specific transactions made by Novozymes under a share buyback program ('aktietilbagekøbsprogram') between February 11, 2011, and December 31, 2011, reporting the number of shares bought and the average price for specific dates (March 21 to March 24, 2011). It concludes by stating the total number of own shares held. This content directly relates to the company repurchasing or selling its own shares, which corresponds precisely to the 'Transaction in Own Shares' category.
2011-03-25 English
Report Publication Announcement 2011
Report Publication Announcement Classification · 99% confidence The document text is very short (341 characters) and announces a change in how Novozymes will structure and report its enzyme sales areas to the financial markets. It does not contain the detailed financial data of an Annual Report (10-K) or Interim Report (IR), nor is it a transcript (CT) or a formal management discussion (MDA). Since it is an announcement regarding a change in reporting structure/segmentation that affects financial communication, it is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the change is deemed significant enough to impact segment reporting, but RNS is the safer general regulatory announcement fallback for structural changes not covered by other specific codes. Given the context of changing 'disclosed and reported to the financial markets' structure, RNS is the most appropriate general regulatory announcement category.
2011-03-23 English
Earnings Release 2011
Earnings Release Classification · 99% confidence The document is a press release dated March 23, 2011, announcing a restructuring of Novozymes' enzyme sales reporting segments to align with internal structure and market communication. It details the old and new segment breakdowns and includes comparative historical financial data (Tables 1 and 2) for 2006-2010, showing quarterly and total sales figures under the previous and new reporting structures. This type of announcement, which details changes in how financial results will be segmented and reported, is a key component of management's explanation of business structure and financial presentation. It is not a full Annual Report (10-K), an Earnings Release (ER) which typically focuses on period results, or a formal Audit Report (AR). It fits best under Management Reports (MDA) as it explains changes in financial reporting methodology and structure, which management is responsible for explaining to investors. It is not a simple announcement of a report (RPA) because it contains substantial explanatory text and detailed comparative tables. Q1 2011
2011-03-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.